探究肿瘤细胞的转移机制、准确预测患者的预后是乳腺肿瘤治疗尤为重要的问题。研究提示长链非编码RNA（lncRNA）在肿瘤发生发展、转移复发调控中扮演了重要角色。本课题组前期通过高通量芯片技术筛选乳腺癌原发灶与前哨淋巴结转移灶之间的差异表达lncRNA，并通过独立样本验证选定尚无研究报道的lncRNA BMRL1（ENST00000499452）进行后续深入研究。通过前期实验，我们发现lncRNA BMRL1可调控乳腺癌细胞的增殖、迁移、浸润能力，高表达BMRL1的乳腺癌患者的预后相对较差。这提示我们lncRNA BMRL1可影响肿瘤细胞的侵袭转移能力，继而影响乳腺癌患者的预后。本课题组拟在前期研究基础上，通过体内体外实验水平阐明转移相关lncRNA BMRL1及其复合物调控下游相关信号转导通路，继而影响乳腺癌侵袭转移的分子机制，为乳腺癌转移复发研究及预后预测提供新的思路及干预靶点。

Tumor cell metastasis is the major drawback to effective systemic therapies for cancers. There are no clinically useful molecular markers to predict prognosis in the whole breast cancer population. Long non-coding RNA (lncRNA) have diverse function, including the regulation of cellular development, differentiation, proliferation and apoptosis. Aberrant expression of lncRNAs is involved in a number of molecular pathways which are related to the mechanisms of tumor invasion and metastasis. We previously identified differentially expressed lncRNAs between breast tumors and paired metastastic sentinel lymph nodes from gene profiling data. Furthermore, we confirmed that high lncRNA BMRL1 level associated with poor disease free survival in breast cancer patients. Ectopic overexpression of BMRL1 promoted breast cancer cells migration and invasion, however, the detailed mechanisms remain unknown. Our further research is to investigate the role of lncRNA BMRL1 in regulating cancer metastasis, and provide new insights into the prognostic value of lncRNAs.